116.63
price down icon1.60%   -1.90
after-market After Hours: 116.63
loading
Axsome Therapeutics Inc stock is traded at $116.63, with a volume of 656.38K. It is down -1.60% in the last 24 hours and down -8.55% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$118.53
Open:
$115.62
24h Volume:
656.38K
Relative Volume:
0.74
Market Cap:
$5.71B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-17.86
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-9.71%
1M Performance:
-8.55%
6M Performance:
+29.78%
1Y Performance:
+46.15%
1-Day Range:
Value
$113.50
$117.78
1-Week Range:
Value
$113.50
$130.20
52-Week Range:
Value
$64.11
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Name
Axsome Therapeutics Inc
Name
Phone
(212) 332-3241
Name
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Name
Employee
589
Name
Twitter
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
AXSM's Discussions on Twitter

Compare AXSM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AXSM
Axsome Therapeutics Inc
116.63 5.71B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-11-25 Initiated Deutsche Bank Buy
Dec-31-24 Reiterated Mizuho Outperform
Sep-03-24 Initiated Wells Fargo Overweight
Aug-06-24 Upgrade BofA Securities Neutral → Buy
Jul-22-24 Initiated Needham Buy
Apr-29-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-19-24 Initiated Robert W. Baird Outperform
Feb-06-24 Initiated UBS Buy
Jan-25-24 Initiated RBC Capital Mkts Outperform
Dec-13-23 Initiated Citigroup Buy
Aug-08-23 Upgrade BofA Securities Underperform → Neutral
Jan-05-23 Initiated Piper Sandler Neutral
Nov-01-22 Initiated Loop Capital Buy
Sep-07-22 Resumed Mizuho Buy
Aug-10-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-10-21 Initiated Berenberg Buy
Jan-08-21 Initiated Jefferies Buy
Dec-16-20 Initiated Mizuho Buy
Sep-29-20 Initiated BofA Securities Underperform
Sep-10-20 Initiated Morgan Stanley Overweight
Apr-28-20 Reiterated H.C. Wainwright Buy
Apr-14-20 Initiated Cowen Outperform
Dec-30-19 Reiterated H.C. Wainwright Buy
Dec-17-19 Reiterated H.C. Wainwright Buy
Dec-16-19 Reiterated Guggenheim Buy
Oct-16-19 Initiated Guggenheim Buy
Sep-18-19 Initiated William Blair Outperform
May-28-19 Initiated SunTrust Buy
May-23-19 Reiterated H.C. Wainwright Buy
Apr-08-19 Initiated SVB Leerink Outperform
Mar-15-19 Reiterated H.C. Wainwright Buy
Oct-03-16 Resumed Brean Capital Buy
Dec-15-15 Initiated Cantor Fitzgerald Buy
Dec-14-15 Initiated Ladenburg Thalmann Buy
View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

pulisher
07:24 AM

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00 - MarketBeat

07:24 AM
pulisher
02:54 AM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat

02:54 AM
pulisher
Mar 30, 2025

Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9%Here's Why - MarketBeat

Mar 30, 2025
pulisher
Mar 29, 2025

Fox Run Management L.L.C. Makes New $518,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 29, 2025
pulisher
Mar 29, 2025

(AXSM) Proactive Strategies - Stock Traders Daily

Mar 29, 2025
pulisher
Mar 29, 2025

Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 29, 2025
pulisher
Mar 27, 2025

Axsome succeeds in late-stage trial for ADHD therapy - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga

Mar 27, 2025
pulisher
Mar 26, 2025

Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive

Mar 26, 2025
pulisher
Mar 26, 2025

AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat

Mar 26, 2025
pulisher
Mar 26, 2025

Intech Investment Management LLC Acquires 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report - biocentury.com

Mar 25, 2025
pulisher
Mar 25, 2025

Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome’s Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear - insights.citeline.com

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat - Endpoints News

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome shares fall after ADHD trial results By Investing.com - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome stock rises on trial win for ADHD drug (AXSM:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary Endpoints - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

New ADHD treatment shows promise in phase 3 trial - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics' ADHD drug meets main goal in late-stage study - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention - Bluefield Daily Telegraph

Mar 25, 2025
pulisher
Mar 25, 2025

Major Breakthrough: Axsome's ADHD Drug Shows 45% Symptom Reduction in Phase 3 Trial - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Strong Growth and Positive Outlook for Axsome Therapeutics’ Auvelity Drives Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Royce & Associates LP Acquires 14,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Privium Fund Management B.V. Has $5.27 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Raymond James Financial Inc. Purchases Shares of 174,586 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 22, 2025
pulisher
Mar 21, 2025

Axsome: The Alzheimer’s Agitation Program For AXS-05 (NASDAQ:AXSM) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Charles Schwab Investment Management Inc. Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 21, 2025
pulisher
Mar 20, 2025

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Connor Clark & Lunn Investment Management Ltd. Takes $6.22 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 20, 2025
pulisher
Mar 19, 2025

Great Lakes Advisors LLC Sells 3,220 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

How To Trade (AXSM) - Stock Traders Daily

Mar 19, 2025

Axsome Therapeutics Inc Stock (AXSM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):